You are here

Swiss pharma company pays US$5.5b for US capsule maker

19_40855615 - 12_12_2016 - FILE SWITZERLAND ECONOMY LONZA CAPSUGEL.jpg
Swiss pharmaceuticals and life sciences group Lonza said Thursday it had bought US capsule maker Capsugel for US$5.5 billion as it focuses more on health care.

[ZURICH] Swiss pharmaceuticals and life sciences group Lonza said Thursday it had bought US capsule maker Capsugel for US$5.5 billion as it focuses more on health care.

The deal includes refinancing Capsugel's existing debt of US$2 billion and is set to be finalised by the second quarter of 2017, Lonza said in a statement.

Buying Capsugel "meets Lonza's strategic and financial goals", chief executive Richard Ridinger said in the statement.

"It accelerates our healthcare continuum strategy by giving us broader exposure to the fast-growing pharma and consumer healthcare markets," he added.

sentifi.com

Market voices on:

Both companies' boards of directors have approved the deal.

Lonza said that within three years it expected to achieve 30 million Swiss francs (S$42.1 million ) per year in operating synergies and 15 million Swiss francs in tax synergies a year.

Capsugel, which is based in New Jersey, was purchased from Pfizer in 2011 by private equity firm KKR.

AFP

Powered by GET.comGetCom